Misonix, Inc.

If you purchased Misonix, Inc. securities and would like to join the action, please click "Join This Action" below.

MISONIX MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF MISONIX, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – MSON

July 29, 2021.

New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Misonix, Inc. (NASDAQ: MSON) to Bioventus Inc. is fair to Misonix shareholders. Under the terms of the agreement, Misonix stockholders may elect to receive either (i) 1.6839 shares of Bioventus class A common stock or (ii) $28.00 in cash, without interest, for each share of Misonix common stock they hold, subject to proration based on an aggregate maximum cash amount payable by Bioventus equal to $10.50 per share of Misonix common stock outstanding shortly prior to the completion of the transaction.

The investigation concerns whether Misonix and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Misonix shareholders; (2) determine whether Bioventus is underpaying for Misonix; and (3) disclose all material information necessary for Misonix shareholders to adequately assess and value the merger consideration. On behalf of Misonix shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Certification

Scroll to Top